Social Media Sidebar

Announcement

Please sign up, comment on articles and bring your friends!

Current poll

PlanetTech is asking:

What do you think about our new web site?

Love it, indeed
Really good solution
Same as old one
The old one was better
This is a new option

Quote of the day

Just because something doesn’t do what you planned it to do doesn’t mean it’s useless.

 

Thomas Edison

Drug Hopes to Delay Onset of Alzheimer's Symptoms With a Monthly Shot in the Arm

RATE THIS! +46
Posted in Medicine on 28th Dec, 2013 04:13 AM by AlexMuller

Alzheimer’s disease is on the rise, even as doctors continue to struggle to find potential treatments for it. Researchers expect the number of those suffering from dementia to grow from 44 million at present to three times that by 2050.

 
The growing number puts increased pressure on researchers to do something to ameliorate the disease. And one drug is attracting the spotlight as it enters clinical trials. Eric Karran, the director of research at Alzheimer’s Research UK, said in a press conference in the lead-up to a G8 summit on dementia that he is “full of hope” that a drug now being tested in the United States on patients with mild dementia may be to Alzheimer’s disease what statins are to heart disease.
 
The drug, called solanezumab, appears to slow the buildup of amyloid beta in the brain and improves cognitive function in patients with mild dementia when given as a monthly shot.
 
But the excitement about the drug is as much a measure of other treatments’ failures as it is of its success. Researchers don’t even know for sure that amyloid beta causes Alzheimer’s-related dementia, although it is clearly linked. And solanezumab has already been shown not to help those whose dementia is more than mild.
 
In a clinical trial on patients with mild and moderate dementia, the results first showed no cognitive improvements. It was only after researchers re-crunched the data, which included standard mental tests used on patients with dementia, that they found improvements in patients with mild dementia hiding in the overall results.
 
Other drugs that have showed promise in the lab have sometimes affected amyloid beta levels but have not produced even these small cognitive improvements in Alzheimer’s patients.
 
“The marginal benefits of solanezumab are encouraging to support continued evaluation in future studies, and offer small support in favor of the ongoing viability of the ‘amyloid cascade hypothesis,’” Harvard researchers tepidly concluded in a recent review of the literature on the drug.

Tags: Alzheimer'sbrainneuroscienceneuronsdementiasolanezumabamyloid

Read original article » Back to category

Comments

Author: Guest
Posted: 2013-12-28
+2
Problem of dementia finally has been recognised as global problem and some funds are coming but the road to cure or help with symptoms relay on more research
3 Replies
Author: Guest
Posted: 2013-12-28
+1
Dementia is a serious disease and the predicted numbers are alarming. Like with cancer, research needs more funding
3 Replies
Author: Guest
Posted: 2013-12-28
+1
Some good news on funding recently. Leading nations have committed to developing a cure or treatment for dementia by 2025 at the G8 dementia summit. Health ministers meeting in London said G8 countries would increase funding for research to meet that goal. Reply
Author: Guest
Posted: 2013-12-28
+0
The summit also called on the World Health Organization to identify dementia as "an increasing threat to global health" and to help countries adapt to the dementia timebomb. Reply
Reply
Reply
Author: Guest
Posted: 2013-12-28
+2
Scientists believe that the physical changes related to Alzheimer’s disease begin as many as 10 years before symptoms appear. So, the best use of solanezumab would be as a preventative for those at elevated risk of developing Alzheimer’s disease
3 Replies
Author: Guest
Posted: 2013-12-28
+0
There are more than 100 clinical trials under way for drugs that target Alzheimer’s disease. Just a few are testing drugs that would treat the disease directly, rather than treating its symptoms. Reply
Author: Guest
Posted: 2013-12-28
+0
The current solanezumab trial will include only patients with mild dementia. It hopes to show that over time, even modest improvements can mean several years with better quality of life. But the real question that it needs to answer is how much it will help patients Reply
Reply
Author: Guest
Posted: 2013-12-28
+1
Alzheimer's disease is a serious problem and new research and understanding will help. It is most common cause of dementia linked to a set of symptoms which can include loss of memory, mood changes, and problems with communication and reasoning.
5 Replies
Author: Guest
Posted: 2013-12-28
+1
It is likely that a combination of factors, including age, genetic inheritance, environmental factors, lifestyle and overall general health, are responsible. Age appears to be a prominent factor of most of these neurodegenerative disorders
1 Replies
Author: Guest
Posted: 2013-12-28
+0
Yes, and our population is ageing bringing all such diseases to our attention more and more Reply
Reply
Author: Guest
Posted: 2013-12-28
+0
Amyloid proteins are important whatever the cause- they are abnormally folded, which causes them to build up in tissues and organs, leading to organ failure. Reply
Author: Guest
Posted: 2013-12-28
+0
There are more than 20 different proteins that can misfold and form amyloid, which is why there are many different types of systemic amyloidosis- serious disease in each case Reply
Reply
Author: Guest
Posted: 2013-12-28
+1
Dementia has been linked to diabetes recently. So, lifestyle improvements should be considered
1 Replies
Author: Guest
Posted: 2013-12-28
+0
The fact that so many diseases are caused by bad lifestyle is pointing that either the message is not going through or that people are not sure that it is right Reply
Reply


 

Recent headlines

  • Posted in Medicine on 2018-11-17 12:31:22
    Anti-aging compounds targeting Alzheimer’s move closer.....read more
    Posted in Hardware on 2018-11-13 05:19:55
    NASA certifies SpaceX's Falcon 9 for its most expensive.....read more
    Posted in Software on 2018-11-09 03:19:01
    OpenAI launches reinforcement learning training..read more
    Posted in Science on 2018-11-08 03:58:12
    Plan to find and explore Ocean Worlds and search for life..read more
    Posted in Medicine on 2018-11-06 01:18:21
    Glowing chemical 'could aid brain cancer surgery'..read more
Posted in Business on 2013-10-10 01:33
China is working towards a manned lunar mission in about.....read more
Posted in Business on 2013-10-20 07:17
Spacex says China is their main competitor for commercial.....read more
Posted in Software on 2013-10-20 06:43
Pirate Bay Browser Clocks 1,000,000 Downloads..read more
Posted in Medicine on 2013-10-10 02:10
Google reportedly investing hundreds of millions into new.....read more
Posted in Medicine on 2013-10-14 03:13
Endothelial Cells Can Repair and Regenerate Organs,.....read more
Posted in Science on 01.01.2010
Spacex says China is their main competitor for commercial.....read more
Posted in Science on 01.01.2010
Staring at Your Phone Could Be Making You Short Sighted..read more
Posted in Science on 01.01.2010
Oculus Rift virtual reality headset coming to mobile, but.....read more
Posted in Science on 01.01.2010
China is working towards a manned lunar mission in about.....read more
Posted in Science on 01.01.2010
Delivering drugs via nanoparticles to target mitochondria..read more

Recent Blog Posts

  • Posted by AlexMuller
    Even light drinking increases risk of death..read more
    Posted by AlexMuller
    Researchers have discovered how to slow aging..read more
    Posted by AlexMuller
    Human retinas grown in a dish explain how color vision develops..read more
    Posted by AlexMuller
    The smartphone app that can tell you’re depressed before you.....read more
    Posted by AlexMuller
    Neural networks don’t understand what optical illusions are..read more

Login to your Account

Login to your PlanetTech Account here

Username:
Password:
Remember me
or

Create a New Account

You just need username and password

The following errors occured:
Username:
Email:
Password:
Verify password:
Remember me